Last Price$74.18NASDAQ Previous Close - Last Trade as of 3:59PM ET 4/01/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$69.01 (1)
Ask (Size)$74.68 (1)
Day Low / HighN/A - N/A

View Biotechnology IndustryPeer Comparison as of 04/01/2020


Incyte Corp ( NASDAQ )

Price: $74.18
Change: +0.95 (1.30%)
Volume: 104.00
3:59PM ET 4/01/2020

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $83.59
Change: -0.91 (1.08%)
Volume: 25.00
3:59PM ET 4/01/2020

Seattle Genetics Inc ( NASDAQ )

Price: $111.23
Change: -0.01 (0.01%)
Volume: 20.00
4:00PM ET 4/01/2020

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $89.94
Change: +0.01 (0.01%)
Volume: 3.00
4:00PM ET 4/01/2020

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $104.54
Change: -4.31 (3.96%)
Volume: 742.7 K
4:00PM ET 4/01/2020

Read more news Recent News

2020 and Q1 Estimates for Incyte Scaled Up but 2021 Earnings Number Falls
5:40AM ET 4/02/2020 MT Newswires

Consensus estimates for Incyte Corp's (NASDAQ:INCY, Recent Price: 74.18) Q1 ending March 31, 2020, and the full year forecasts for 2020 and 2021 have been...

--Analyst Actions: Morgan Stanley Upgrades Incyte to Overweight From Equal Weight, Lifts PT to $90 From $83
10:13AM ET 4/01/2020 MT Newswires

Price: 72.59, Change: -0.64, Percent Change: -0.87 ...

2020, 2021, and Q1 Earnings Estimates for Incyte Trimmed
1:55AM ET 3/26/2020 MT Newswires

Incyte Corp's (NASDAQ:INCY, Recent Price: 67.43) forecasted earnings estimates for Q1 ending March 31, 2020, and the expectations for 2020 and 2021 have...

--Analyst Actions: Oppenheimer Cuts Incyte's PT to $85 From $99 as COVID-19 Interrupts Office Visits, New Prescriptions; Outperform Rating Kept
10:21AM ET 3/25/2020 MT Newswires

Price: 68.04, Change: +0.61, Percent Change: +0.90 ...

Company Profile

Business DescriptionIncyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE. View company web site for more details
Address1801 Augustine Cut-Off
Wilmington, Delaware 19803
Number of Employees1,367
Recent SEC Filing04/01/20204
Chairman, President & Chief Executive OfficerHervé Hoppenot
Chief Financial Officer & Executive Vice PresidentChristiana Stamoulis
Chief Medical Officer & Executive Vice PresidentSteven H. Stein
Chief Scientific Officer & Executive VPDashyant Dhanak

Company Highlights

Price Open$72.05
Previous Close$74.18
52 Week Range$62.48 - 96.79
Market Capitalization$16.1 B
Shares Outstanding216.8 M
SectorHealth Technology
Next Earnings Announcement05/05/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings33.64
Earnings per Share$2.01
Beta vs. S&P 500N/A
Revenue$1.9 B
Net Profit Margin20.70%
Return on Equity19.11%

Analyst Ratings as of 04/01/2020

Consensus RecommendationConsensus Icon
Powered by Factset